Single User License
INR 742053
Site License
INR 1484105
Corporate User License
INR 2226158

Service Tax Additional

select a format
Price

Single User License
USD 10995
Site License
USD 21990
Corporate User License
USD 32985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


PharmaPoint: Melanoma-Global Drug Forecast Market Analysis to 2023

PharmaPoint: Melanoma-Global Drug Forecast Market Analysis to 2023


  Request for Sample Report

Executive Summary

PharmaPoint: Melanoma-Global Drug Forecast and Market Analysis to 2023

Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately USD 1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching USD 5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. GlobalData expects, by the end of the forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market (including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share of the melanoma market.

The melanoma pipeline is strong; however, GlobalData expects none of these drugs to have a major impact on the overall melanoma market, as the market is crowded with effective immunotherapies and BRAF mutation-targeted agents. The challenge for new entrants into the melanoma market is to find patient populations that are currently underserved. One of the opportunities for the companies is to work cooperatively to develop novel combinations of immuno/targeted-therapies.

Highlights

Key Questions Answered

The melanoma space is filled with the excitement of recently approved anti-PD-1 immunotherapies, which are expected to revolutionize the treatment landscape. What will be the impact of these newly approved drugs and their projected label expansions on the melanoma sales?

As the melanoma market is getting increasingly crowded with multiple anti-PD-1 immunotherapies and BRAF mutation-targeted agents, opportunities for new entrants become limited. What R&D strategies are being used by drug makers to remain competitive?

The survival of patients with metastatic melanoma remains short, especially for those who do not response to anti-PD-1 immunotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the melanoma market?

Key Findings

One of the main drivers of the enormous expansion of the gout market will be the launch of premium-priced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations. These drugs will extend treatment duration and replace cheaper, generic, chemotherapy regimens.

Another strong driver will be the label extension of current therapies into the new settings; for example, PD-1s will garner label extension for the first-line treatment in 2015-16, and the metastatic brands are expected to be approved in the adjuvant setting in the second half of the forecast period.

Companies are focusing on the development of combination immunotherapies, trying to improve the response rate and response duration of drugs.

One of the largest unmet needs is a need for efficacious treatment options for BRAF wild-type patients. Approximately half of melanoma patients do not have BRAF mutations, and are therefore non-eligible for BRAF/MEK inhibitor treatments. Other unmet needs include therapies for PD-1 immunotherapy non-responders, adjuvant treatment for patients with resected melanoma, effective treatment for brain metastasis, and predictive markers for therapeutic response to immunotherapies.

Scope

Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in six patient segments (including adjuvant, BRAF mutated and BRAF wild-type), forecast from 2013 to 2023.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.

Analysis of the current and future market competition in the global melanoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons To Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents

1 Table of Contents 10

1.1 List of Tables 17

1.2 List of Figures 23

2 Introduction 26

2.1 Catalyst 26

2.2 Related Reports 27

2.3 Upcoming Related Reports 27

3 Disease Overview 28

3.1 Etiology and Pathophysiology 28

3.1.1 Etiology 28

3.1.2 Pathophysiology 28

3.1.3 Melanoma Biomarkers 29

3.2 Clinical Staging 30

3.3 Symptoms 32

3.4 Prognosis 32

3.5 Quality of Life 34

4 Epidemiology 35

4.1 Disease Background 35

4.2 Risk Factors and Comorbidities 35

4.3 Global Trends 38

4.3.1 US 39

4.3.2 5EU 39

4.3.3 Japan and Australia 39

4.4 Forecast Methodology 40

4.4.1 Sources Used 42

4.4.2 Sources Not Used 49

4.4.3 Forecast Assumptions and Methods 49

4.5 Epidemiological Forecast for Melanoma (2013-2023) 52

4.5.1 Diagnosed Incident Cases of Melanoma 52

4.5.2 Age-Specific Diagnosed Incident Cases of Melanoma 54

4.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma Skin Cancer 56

4.5.4 Age-Standardized Diagnosed Incidence Rates 58

4.5.5 Pathological Stage at Diagnosis 60

4.5.6 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer 61

4.5.7 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer by Genetic Aberrations 63

4.6 Discussion 65

4.6.1 Epidemiological Forecast Insight 65

4.6.2 Limitations of the Analysis 66

4.6.3 Strengths of the Analysis 67

5 Disease Management 68

5.1 Diagnosis Overview 68

5.2 Treatment Overview 69

5.2.1 Localized Melanoma: Stage 0 to Stage IIC 71

5.2.2 Regional Melanoma: Stage IIIA to Stage IIIC 72

5.2.3 Unresectable and Metastatic Melanoma: Stage III and Stage IV 75

5.3 US 81

5.3.1 Screening and Diagnosis 82

5.3.2 Clinical Practices 84

5.4 France 86

5.4.1 Screening and Diagnosis 87

5.4.2 Clinical Practices 87

5.5 Germany 88

5.5.1 Screening and Diagnosis 89

5.5.2 Clinical Practices 90

5.6 Italy 93

5.6.1 Screening and Diagnosis 94

5.6.2 Clinical Practices 94

5.7 Spain 96

5.7.1 Screening and Diagnosis 97

5.7.2 Clinical Practices 97

5.8 UK 98

5.8.1 Screening and Diagnosis 99

5.8.2 Clinical Practices 99

5.9 Japan 101

5.9.1 Screening and Diagnosis 101

5.9.2 Clinical Practices 102

5.10 Australia 103

5.10.1 Screening and Diagnosis 104

5.10.2 Clinical Practices 105

6 Competitive Assessment 108

6.1 Overview 108

6.2 Interferon-based Adjuvant Therapies 110

6.2.1 Roferon-A (Interferon Alfa-2a) 110

6.2.2 Intron A (Interferon Alfa-2b) 114

6.2.3 Sylatron (Peginterferon Alfa-2b) 118

6.3 Immune Checkpoint Inhibitors 124

6.3.1 Yervoy (Ipilimumab) 124

6.3.2 Opdivo (Nivolumab) 134

6.3.3 Keytruda (Pembrolizumab) 143

6.4 BRAF Mutation-targeted Therapies 151

6.4.1 Zelboraf (Vemurafenib) 151

6.4.2 Tafinlar (Dabrafenib) 158

6.4.3 Mekinist (Trametinib) 164

6.5 Other Therapeutic Classes 176

7 Unmet Need and Opportunity 178

7.1 Overview 178

7.2 Therapeutic Options for BRAF Wild-Type Patients 180

7.2.1 Unmet Need 180

7.2.2 Gap Analysis 181

7.2.3 Opportunity 182

7.3 Therapies for Non-responders to PD-1 Immunotherapy 183

7.3.1 Unmet Need 183

7.3.2 Gap Analysis 184

7.3.3 Opportunity 186

7.4 Adjuvant Therapies for High-Risk Resectable Melanoma 188

7.4.1 Unmet Need 188

7.4.2 Gap Analysis 189

7.4.3 Opportunity 191

7.5 Effective Treatment for Brain Metastases 193

7.5.1 Unmet Need 193

7.5.2 Gap Analysis 194

7.5.3 Opportunity 196

7.6 Predictive Markers for Therapeutic Response to Immunotherapies 197

7.6.1 Unmet Need 197

7.6.2 Gap Analysis 198

7.6.3 Opportunity 200

8 Pipeline Assessment 201

8.1 Overview 201

8.2 Promising Drugs in Clinical Development 202

8.3 RAF/RAS/MEK Pathway-Targeting Therapies 204

8.3.1 Cobimetinib (GDC-0973) 204

8.3.2 Encorafenib (LGX818) 211

8.3.3 Binimetinib (MEK162) 217

8.4 Immune-Related Therapies 224

8.4.1 Talimogene Laherparepvec 224

8.4.2 Eltrapuldencel-T (NSB20) 232

8.4.3 Seviprotimut-L (POL-103A) 238

8.4.4 PV-10 244

8.5 Promising Drugs in Early-Stage Development 250

8.5.1 PI3K/Akt/mTOR Pathway-Targeting Therapies 250

8.5.2 Cell Cycle Checkpoint Inhibitors 252

8.5.3 Next-Generation BRAF Inhibitors 254

8.5.4 Immunotherapies 256

8.5.5 Antibody-Drug Conjugates 259

8.6 Other Drugs in Development 261

9 Current and Future Players 263

9.1 Overview 263

9.2 Trends in Corporate Strategy 266

9.3 Company Profiles 267

9.3.1 Bristol-Myers Squibb 267

9.3.2 Novartis 270

9.3.3 Roche 273

9.3.4 Merck 276

10 Market Outlook 280

10.1 Global Markets 280

10.1.1 Forecast 280

10.1.2 Drivers and Barriers � Global Issues 284

10.2 United States 286

10.2.1 Forecast 286

10.2.2 Key Events 290

10.2.3 Drivers and Barriers � US 291

10.3 5EU 293

10.3.1 Forecast 293

10.3.2 Key Events 297

10.3.3 Drivers and Barriers � France 298

10.3.4 Drivers and Barriers � Germany 300

10.3.5 Drivers and Barriers � Italy 301

10.3.6 Drivers and Barriers � Spain 303

10.3.7 Drivers and Barriers � UK 304

10.4 Japan 306

10.4.1 Forecast 306

10.4.2 Key Events 309

10.4.3 Drivers and Barriers � Japan 309

10.5 Australia 311

10.5.1 Forecast 311

10.5.2 Key Events 314

10.5.3 Drivers and Barriers � Australia 315

11 Appendix 317

11.1 Bibliography 317

11.2 Abbreviations 344

11.3 Methodology 349

11.4 Forecasting Methodology 349

11.4.1 Diagnosed Melanoma Patients 349

11.4.2 Percent Drug-Treated Patients 350

11.4.3 Drugs Included in Each Therapeutic Class 350

11.4.4 Launch and Patent Expiry Dates 351

11.4.5 General Pricing Assumptions 352

11.4.6 Average Body Weight and Surface Area Across the 8MM 353

11.4.7 Individual Drug Assumptions 354

11.4.8 Generic Erosion 368

11.4.9 Pricing of Pipeline Agents 368

11.5 Primary Research-KOLs Interviewed for this Report 370

11.6 Primary Research-Prescriber Survey 373

11.7 About the Authors 374

11.7.1 Analyst 374

11.7.2 Therapy Area Director 374

11.7.3 Epidemiologist 375

11.7.4 Global Head of Healthcare 375

11.8 About GlobalData 376

11.9 Disclaimer 376

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Ages ?20 Years, Both Sexes, N, 2013-2023 53

Figure 2: Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, N, 2013 56

Figure 3: Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin (N), 2013 58

Figure 4 : Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ?20 Years, 2013 60

Figure 5: Distribution of Incident Cases of Melanoma Skin Cancer by Stage at Diagnosis (%) 61

Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, Ages ?20 Years, N, 2013-2023 63

Figure 7: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with BRAF Mutations, Both Sexes, Ages ?20 Years, N, 2013 64

Figure 8: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with NRAS Mutations, Both Sexes, Ages ?20 Years, 2013 65

Figure 9: Treatment Flowchart for Localized Melanoma 72

Figure 10: Treatment Flowchart for Regional Melanoma 73

Figure 11: Treatment Flowchart for Recurrent Melanoma 75

Figure 12: Treatment Flowchart for Metastatic Melanoma 77

Figure 13: Yervoy's Development in Melanoma 127

Figure 14: Opdivo's Development in Melanoma 137

Figure 15: Keytruda's Development in Melanoma 146

Figure 16: Zelboraf's Development in Melanoma 154

Figure 17: Mekinist's Development in Melanoma 168

Figure 18: Melanoma � Phase III Pipeline, 2015 203

Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Melanoma, 2013-2023 204

Figure 20: Cobimetinib's Development in Melanoma 206

Figure 21: Clinical and Commercial Positioning of Cobimetinib 209

Figure 22: Encorafenib's Development in Melanoma 213

Figure 23: Clinical and Commercial Positioning of Encorafenib 215

Figure 24: Binimetinib's Development in Melanoma 219

Figure 25: Clinical and Commercial Positioning of Binimetinib 222

Figure 26: Talimogene Laherparepvec's Development in Melanoma 227

Figure 27: Clinical and Commercial Positioning of Talimogene Laherparepvec 230

Figure 28: Eltrapuldencel-T's Development in Melanoma 234

Figure 29: Clinical and Commercial Positioning of Eltrapuldencel-T 236

Figure 30: Seviprotimut-L's Development in Melanoma 240

Figure 31: Clinical and Commercial Positioning of Seviprotimut-L 242

Figure 32: PV-10's Development in Melanoma 246

Figure 33: Clinical and Commercial Positioning of PV-10 248

Figure 34: Global Sales of Branded Products for Melanoma by Company, 2013-2023 265

Figure 35: Company Portfolio Gap Analysis in Melanoma, 2013-2023 266

Figure 36: Bristol-Myers Squibb SWOT Analysis in Melanoma, 2013-2023 270

Figure 37: Novartis SWOT Analysis in Melanoma, 2013-2023 273

Figure 38: Roche SWOT Analysis in Melanoma, 2013-2023 276

Figure 39: Merck SWOT Analysis in Melanoma, 2013-2023 279

Figure 40: Global Sales for Melanoma by Region, 2013-2023 283

Figure 41: Sales for Melanoma in the United States by Drug Class, 2013-2023 289

Figure 42: Sales for Melanoma in the EU by Drug Class, 2013-2023 296

Figure 43: Sales for Melanoma in Japan by Drug Class, 2023 308

Figure 44: Sales for Melanoma in Australia by Drug Class, 2013-2023 313

1.1 List of Tables

Table 1: Stage Definitions for Melanoma 31

Table 2: The ABCED Rule of Melanoma Detection 32

Table 3: Prognosis of Melanoma 33

Table 4: Risk Factors and Comorbidities for Melanoma of the Skin 37

Table 5: Melanoma of the Skin Staging Definition Equivalencies 41

Table 6: 8MM, Sources of Melanoma of the Skin Incidence Data 42

Table 7: 8MM, Sources of Melanoma of the Skin Incident Cases by Pathological Stage at Diagnosis Data 44

Table 8: 8MM, Sources of Melanoma of the Skin Five-Year Diagnosed Prevalent Cases by Stage Data 45

Table 9: 8MM, Sources of Melanoma of the Skin Diagnosed Prevalent Cases by Genetic Aberration 46

Table 10: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, Ages ?20 Years, N, Select Years 2013-2023 53

Table 11: 8MM, Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, N (Row%), 2013 55

Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin, Ages ?20 Years, N (Row %), 2013 57

Table 13: Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ?20 Years, 2013 59

Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, ?20 years, N, Select Years 2013-2023 62

Table 15: Clinical Guidelines for Melanoma 70

Table 16: Most Prescribed Drugs for Melanoma by Class in the Global Markets, 2013 81

Table 17: Country Profile � US 82

Table 18: Country Profile � France 86

Table 19: Country Profile � Germany 89

Table 20: Country Profile � Italy 93

Table 21: Country Profile � Spain 96

Table 22: Country Profile � UK 98

Table 23: Country Profile � Japan 101

Table 24: Country Profile � Australia 103

Table 25: Leading Treatments for Melanoma, 2013 109

Table 26: Product Profile � Roferon-A 111

Table 27: Safety of Roferon-A 112

Table 28: Roferon-A SWOT Analysis, 2015 113

Table 29: Global Sales Forecast (USD m) for Roferon-A, 2013-2023 114

Table 30: Product Profile � Intron A 115

Table 31: Efficacy of Intron A (E1684) 116

Table 32: Safety of Intron A (E1684, E1690, and E1694) 117

Table 33: Intron A SWOT Analysis, 2015 117

Table 34: Global Sales Forecast (USD m) for Intron A, 2013-2023 118

Table 35: Product Profile � Sylatron 120

Table 36: Efficacy of Sylatron (EORTC 18991, NCT00006249) 121

Table 37: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon 122

Table 38: Safety of Sylatron 123

Table 39: Sylatron SWOT Analysis, 2015 123

Table 40: Global Sales Forecast (USD m) for Sylatron, 2013-2023 124

Table 41: Product Profile � Yervoy 126

Table 42: Efficacy of Yervoy 128

Table 43: Comparison of Higher Dose Yervoy and Dacarbazine (NCT00324155) 129

Table 44: Network Meta-analysis of Yervoy 130

Table 45: Safety of Yervoy at 3mg/kg (NCT00094653) 131

Table 46: Safety Data from Yervoy Dose-Escalation Study (NCT00289640) 132

Table 47: Yervoy SWOT Analysis, 2015 133

Table 48: Global Sales Forecast (USD m) for Yervoy, 2013-2023 134

Table 49: Product Profile � Opdivo 137

Table 50: Efficacy of Opdivo 139

Table 51: Efficacy of Opdivo in BRAF Wild-Type Advanced Melanoma (NCT01721772) 140

Table 52: Safety Data from Opdivo Dose-Escalation Study (NCT00730639) 141

Table 53: Safety Data from the CheckMate-037 Trial (NCT01721746) 141

Table 54: Opdivo SWOT Analysis, 2015 142

Table 55: Global Sales Forecast (USD m) for Opdivo, 2013-2023 143

Table 56: Product Profile-Keytruda 146

Table 57: Efficacy of Keytruda from KEYNOTE-001 (NCT01295827) 147

Table 58: Efficacy of Keytruda from KEYNOTE-002 (NCT01704287) 148

Table 59: Safety of Keytruda 149

Table 60: Keytruda SWOT Analysis, 2015 150

Table 61: Global Sales Forecasts (USD m) for Keytruda, 2013-2023 151

Table 62: Product Profile � Zelboraf 153

Table 63: Efficacy of Zelboraf 155

Table 64: Safety of Zelboraf 156

Table 65: Zelboraf SWOT Analysis, 2015 157

Table 66: Global Sales Forecasts (USD m) for Zelboraf, 2013-2023 158

Table 67: Product Profile � Tafinlar 160

Table 68: Efficacy of Tafinlar 161

Table 69: Safety of Tafinlar 162

Table 70: Tafinlar SWOT Analysis, 2015 163

Table 71: Global Sales Forecast (USD m) for Tafinlar, 2013-2023 164

Table 72: Product Profile � Mekinist 167

Table 73: Efficacy of Mekinist 169

Table 74: Efficacy Results of the COMBI-d Trial (NCT01584648) 170

Table 75: Efficacy Results of the COMBI-v Trial (NCT01072175) 171

Table 76: Safety of Mekinist 172

Table 77: Safety Results of the COMBI-d trial (NCT01584648) 173

Table 78: Safety Results of the COMBI-v trial (NCT01584648) 174

Table 79: Mekinist SWOT Analysis, 2015 175

Table 80: Global Sales Forecasts (USD m) for Mekinist, 2013-2023 176

Table 81: Summary of Minor Therapeutic Classes, 2013 177

Table 82: Unmet Needs and Opportunities in Melanoma 180

Table 83: Product Profile � Cobimetinib 206

Table 84: Efficacy of the Zelboraf/Cobimetinib Combination 207

Table 85: Safety of the Zelboraf/Cobimetinib Combination 208

Table 86: Cobimetinib SWOT Analysis, 2015 210

Table 87: Global Sales Forecast (USD m) for Cobimetinib, 2013-2023 211

Table 88: Product Profile � Encorafenib 213

Table 89: Efficacy of Encorafenib 214

Table 90: Encorafenib SWOT Analysis, 2015 216

Table 91: Global Sales Forecasts (USD m) for Encorafenib, 2013-2023 217

Table 92: Product Profile � Binimetinib 219

Table 93: Efficacy of Binimetinib (NCT01320085) 220

Table 94: Safety of Binimetinib (NCT01320085) 221

Table 95: Binimetinib SWOT Analysis, 2015 223

Table 96: Global Sales Forecasts (USD m) for Binimetinib, 2013-2023 224

Table 97: Product Profile � Talimogene Laherparepvec 227

Table 98: Efficacy of Talimogene Laherparepvec 228

Table 99: Safety of Talimogene Laherparepvec 229

Table 100: Talimogene Laherparepvec SWOT Analysis, 2015 231

Table 101: Global Sales Forecast (USD m) for Talimogene Laherparepvec, 2013-2023 232

Table 102: Product Profile-Eltrapuldencel-T 234

Table 103: Efficacy of Eltrapuldencel-T 235

Table 104: Eltrapuldencel-T SWOT Analysis, 2015 237

Table 105: Global Sales Forecast (USD m) for Eltrapuldencel-T, 2013-2023 238

Table 106: Product Profile � Seviprotimut-L 240

Table 107: Efficacy of Seviprotimut-L 241

Table 108: Seviprotimut-L SWOT Analysis, 2015 243

Table 109: Global Sales Forecast (USD m) for Seviprotimut-L, 2013-2023 244

Table 110: Product Profile � PV-10 245

Table 111: Efficacy of PV-10 246

Table 112: Safety of PV-10 247

Table 113: PV-10 SWOT Analysis, 2015 249

Table 114: Global Sales Forecast (USD m) for PV-10, 2013-2023 250

Table 115: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway 252

Table 116: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints 254

Table 117: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors 255

Table 118: Clinical Settings of Early-Stage Immunotherapies 259

Table 119: Clinical Settings of Early-Stage Antibody-drug Conjugates 260

Table 120: Drugs in Development, 2015 261

Table 121: Key Companies in the Melanoma Market in the 8MM, 2013-2023 264

Table 122: BMS' Melanoma Portfolio Assessment, 2015 269

Table 123: Novartis' Melanoma Portfolio Assessment, 2015 272

Table 124: Roche's Melanoma Portfolio Assessment, 2015 275

Table 125: Merck's Melanoma Portfolio Assessment, 2015 278

Table 126: Global Sales Forecast (USD m) for Melanoma, 2013-2023 282

Table 127: Melanoma Market � Drivers and Barriers, 2015 284

Table 128: Sales Forecast (USD m) for Melanoma in the United States, 2013-2023 288

Table 129: Key Events Impacting Sales for Melanoma in the United States, 2013-2023 290

Table 130: Melanoma Market in the United States-Drivers and Barriers, 2015 291

Table 131: Sales Forecast (USD m) for Melanoma in the 5EU, 2013-2023 295

Table 132: Key Events Impacting Sales for Melanoma in the 5EU, 2013-2023 297

Table 133: Melanoma Market in France � Drivers and Barriers, 2015 298

Table 134: Melanoma Market in Germany � Drivers and Barriers, 2015 300

Table 135: Melanoma Market in Italy � Drivers and Barriers, 2015 301

Table 136: Melanoma Market in Spain � Drivers and Barriers, 2015 303

Table 137: Melanoma Market in the United Kingdom � Drivers and Barriers, 2015 304

Table 138: Sales Forecast (USD m) for Melanoma in Japan, 2013-2023 308

Table 139: Key Events Impacting Sales for Melanoma in Japan, 2013-2023 309

Table 140: Melanoma Market in Japan-Drivers and Barriers, 2015 309

Table 141: Sales Forecast (USD m) for Melanoma in Australia, 2013-2023 312

Table 142: Key Events Impacting Sales for Melanoma in Australia, 2013-2023 314

Table 143: Melanoma Market in Australia-Drivers and Barriers, 2015 315

Table 144: Key Launch Dates 351

Table 145: Key Patent Expiries 352

Table 146 Average Body Weight and Surface Area Across the 8MM 353

Table 147: High-Prescribing Physicians Surveyed by Country 373

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bristol-Myers Squibb

Novartis

Roche

Merck


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com